Biovica signs master service agreement for TKa testing with leading pharma company

2024-03-07 08:00

Biovica, active in blood-based cancer monitoring, has signed a master service agreement with a leading tier-1 pharmaceutical company, enabling Biovica to provide its TKa testing assay and testing services. The agreement holds room for several expected work orders, the first of which is 1.7 MSEK.

This service agreement enables the evaluation of cell proliferation activities in pivotal drug development studies. The test service is focused on the use of the Biovica’s TKa assay and expertise within the interpretation of TKa measurement dynamics.

"This agreement confirms the Pharma interest in using our assay to measure changes in tumor cell proliferation during drug development activities and potentially further leading into the development of a Companion Diagnostic (CDx) product. It is an important step for Biovica to support pharma in the development of new improved cancer therapies that benefit cancer patients," said Anders Rylander, CEO of Biovica.


Numbers of patients in studies




Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program